COMPASS Pathways investor relations material

COMPASS Pathways plc, a mental health care company, develops psilocybin therapy through bio-pharmaceutical research. The company conducts a clinical trial on the effectiveness of new therapies for depression; and offers COMP360, a formulation of psilocybin for the treatment-resistant depression. It is also developing COMP515, a formulation of psilocybin for Major Depressive Disorder. COMPASS Pathways plc was founded in 2016 and is headquartered in London, the United Kingdom.